Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs TAK 003 (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 06 Feb 2019 Status changed from active, no longer recruiting to completed.
    • 01 Aug 2018 Planned End Date changed from 28 Nov 2018 to 28 Jan 2019.
    • 01 Aug 2018 Planned primary completion date changed from 16 Jun 2018 to 28 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top